We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 2

1.
Figure 1

Figure 1. Single-cycle replication capacities of HIV-2 integrase variants.. From: Three Main Mutational Pathways in HIV-2 Lead to High-Level Raltegravir and Elvitegravir Resistance: Implications for Emerging HIV-2 Treatment Regimens.

Each datum point is the infectious titer [MAGIC-5A focus-forming units (FFU)/ml] produced by an independent transfection of full-length HIV-2 plasmid DNA into 293T-17 cells. Bars indicate the mean titers for each wild-type (WT) or mutant strain. Light-grey bars indicate variants that are significantly different from WT (P>0.05) and * indicates a significant difference between Q148R and G140S+Q148R HIV-2 (P>0.01) (ANOVA of log10-transformed titers with Tukey’s post-test). Filled and open circles represent the titers produced by two independent plasmid DNA preparations for each genotype; titers from a third preparation of wild-type DNA are shown as inverted triangles. Error bars indicate standard deviations.

Robert A. Smith, et al. PLoS One. 2012;7(9):e45372.
2.
Figure 2

Figure 2. Susceptibility of HIV-2 integrase variants to raltegravir (RAL) and elvitegravir (EVG).. From: Three Main Mutational Pathways in HIV-2 Lead to High-Level Raltegravir and Elvitegravir Resistance: Implications for Emerging HIV-2 Treatment Regimens.

Panels A and C show the EC50 values for wild-type (WT) HIV-2 ROD9 and each of 13 site-directed ROD9 integrase mutants tested against raltegravir and elvitegravir, respectively. Bars indicate the means of three or more independent dose-response experiments. Light, medium and dark-colored bars indicate low-level, moderate, and highlevel resistance (mean EC50 values 2–5-fold, 6–15-fold and >15-fold relative to wild-type, respectively). With the exception of Q148H versus raltegravir and Y143C versus elvitegravir, EC50 values for all strains shown in color were statistically greater than the corresponding values for wild-type ROD9 (P>0.05, ANOVA of log10-transformed EC50 values with Tukey's post-test). EC50 values for T97A and G140S did not statistically differ from WT for either drug. Panels B and D show representative dose-response data for WT, Q148R, and G140S+Q148R versus raltegravir and WT, N155H, and E92Q+N155H versus elvitegravir, respectively. Titers are expressed as the percentage of those seen in the absence of drug (i.e., % of solvent-only controls) and are the means of three independent cultures at each drug concentration. Error bars in all panels indicate standard deviations.

Robert A. Smith, et al. PLoS One. 2012;7(9):e45372.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk